About 30 to 80% of patients with heart failure (HF) have some sort of cognitive impairment, with a higher risk of dementia than the general population. A component of sacubitril/valsartan inhibits neprilysin—an enzyme involved in amyloid-β peptide degradation (Alzheimer’s disease)—, and that could worsen cognitive impairment. The PERSPECTIVE study is the first randomized trial to…